Anaemia of chronic diseases in rheumatoid arthritis

Justyna Fryc; Stanisław Sierakowski

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2010
vol. 48

Send email

Copy url:

abstract:

Review paper

Anaemia of chronic diseases in rheumatoid arthritis

Justyna Fryc

,

Stanisław Sierakowski

Reumatologia 2010; 48, 6: 421–424

Online publish date: 2010/12/20

View full text Get citation

Anaemia of chronic diseases (ACD) is one of the most common hematologic abnormalities in patients with rheumatoid arthritis. It can be observed in a variety of conditions, including neoplastic, infectious and inflammatory diseases, heart failure or diabetes mellitus. However, until recently, little about its pathogenesis has been known. Inflammatory mediators such as tumour necrosis factor-alpha, interleukin-1, interleukin-6 and interlukin-10 play a role in this disorder. Hepcidin is one of key proteins in pathogenesis of ACD as it decreases iron absorption and iron release from macrophages. The pathogenesis of ACD is presented in this paper. Additionally, this review provides a summary of recent studies investigating the role of blocking interleukin-6 in rheumatoid arthritis patients with ACD. Inhibition of the interleukin-6 receptor with tocilizumab leads to an increase in haemoglobin levels as compared to placebo

keywords:

anaemia, interleukin-6, rheumatoid arthritis

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Anaemia of chronic diseases in rheumatoid arthritis

Justyna Fryc , Stanisław Sierakowski

anaemia, interleukin-6, rheumatoid arthritis

Justyna Fryc

,

Stanisław Sierakowski